NEURON | JUNE 17, 2020

Zetterberg H and Blennow K

Neuron. 2020;106:881-883.

DOI: https://doi.org/10.1016/j.neuron.2020.06.004

Abstract

Currently available biomarkers for Alzheimer’s disease are of limited availability due to high costs and perceived invasiveness. New studies reveal that Alzheimer’s pathologies now can be reliably quantified in vivo using regular blood tests.